
    
      This open label Phase 1 multicenter study is designed to evaluate the safety and maximum
      tolerated dose (MTD) and recommended phase 2 dose (RP2D) of SAR442720 in combination with
      pembrolizumab in participants with solid tumors.

      The expected duration of study intervention for participants may vary, based on progression
      date; median expected duration of study per participant is estimated to be about 10 months
      (up to 1 month for screening, a median of 6 months for treatment, and a median of 3 months
      for long term follow-up).
    
  